Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey Midas. Sorry I thought you had said that in a previous post a while back. No harm meant.
Hi Spidey,
Don't take your posts as attacking in the least. Likewise with mine.
I too had to take a look back when I read these amounts in the quarterly report. The first two, nobody realized it was not going all to Pluristem. The last one, it was immediately realized. Looking back, they are similar. The tweet however, doesn't clarify that whatsoever, and states was awarded to Pluristem. Different and misleading.
Now the only reason I bring all of this up, is when someone thinks we have $18 million in the bank as of Sept 30th, with another $15 million from the raise. People try to think that the grant money adds the full amount to this, which it obviously doesn't. With the whole grant included, it would be closer to $50 million. A nice thought but incorrect.
I stated back then, that at the time of the end of our last quarter, we were just over 3 quarters of cash lest. A little concerning to say the least, that a "late" stage company, would let it get this close. And as soon as money from raise is done, we book the most amount of shows we have ever done.
They do have enough cash right now for the next year I would say, before getting into concerning territory again. But we will have to look carefully at the burn rate, as I'm sure with all the travelling for shows, and increasing of sites and progression of trials, it will surely increase. I will also be watching for the bonuses to the twins for the non dilutive grants. Hopefully they only get 4% (I think that was the number) of the direct to Pluristem cash, not the full grant value. Pretty sad they need to be incentivized to do this type of thing, after being gifted a couple million shares each.
You are correct that you missed the point. If we don't get a contract for ARS within the next year at most, more dilution will be coming our way. That $20 million will not go towards our $5+million/quarter burn. And did you think all of it was going into Pluristem's coffers? Deception. No other way to say it.
So you think the Pluristem tweet was accurate and not misleading whatsoever right? A 75% haircut of what went into our coffers is fine with you. Even Allo was fooled by the deception. No worries there eh.
That is an understatement. Hopefully once more evidence of managements incompetence like this huge deception comes out, some of the beliebers will start to believe the truth.
Not trying to convince the eternal optimists. Wouldn't expect nothing less that you don't mind being deceived, as you obviously we're, by management. This is all for those who actually have an open mind and want factual evidence to back up their claim. Not Lonza or Amgen, or Chinese delegation...the list goes on and on.
No, THAT IS NOT ALL THAT MATTERS!!! What matters is that approximately 75% of that funding doesn't go into their coffers. The fact that they mislead investors is monumental. Obviously YOU thought 100% of the other 2 grants went directly to them, so good for you if you don't mind being mislead. I do!!! I thought the same so don't feel too bad.
Below is their tweet from Oct. 9th. No mention of their small percentage of the grants. By reading this tweet, would one not think 100% was going to Pluristem like you thought? Of course they would. Was that purposely done, since this was when we were making a run to get the price higher for the raise? One could think this could open them up to potential lawsuits from recent raise participants. You can judge for yourself.
"Pluristem Therapeutics is the recipient, of three awards totalling nearly $25 million from the European Unions Horizon program."
Pluristem Therapeutics is the recipient, of three awards totaling nearly $25 million from the European Union’s Horizon 2020 program. $PSTI pic.twitter.com/0HCcIXaI5T
— Pluri (@Pluribiotech) October 9, 2017
Don't be upset that I showed how you skew things to your benefit. There is a big difference from Pluristem getting 100% of the grants directly, which by FACTS, was proven otherwise. $20 million DIRECTLY in their pockets would be a huge difference. Unfortunately what you said is not factual whatsoever.
I have gotten 2 others invested here as well. Luckily for me at least, one was just shy of $2 and the other in the $1.20's. Midas said he's in the same boat. At least with shares, you have the time to wait it out until the end. My options strategy sure sucks with the delay of pretty much everything this management touches. The euphoria and disregard to the longs that are here who's optimism has justifiably changed, is truly shameful, but that's what you would expect considering why many are here. Just try to keep the faith and we may come out of this eventually.
I know it's hard to keep track but here's what you stated. BIG difference don't YA think!!! $20 million of it doesn't help them with their current burn rate. Will only keep it from rising dramatically due to the trial costs. And come again...who doesn't know what they're talking about. LMBO
Scotty...100 % Of The Horizon 2020 Grants Goes Directly To Pluristem For The Trials They Were Granted For ! The Only Exception Is The N-Track Grant Of Which Pluristem Will Receive A Portion Of The Grant For Payment Of The PLX-Cells They Supply For The Study ! Like Ole Eichy, Again You Two...You Have No Idea What You Are Talking About ! Give It Up And Move On !
And that my friends, shows how misleadimg this management is. Even on their Twitter account that Allo posted, they bragged about 27 or so million in grants. Pretty much a lie if you ask me. But no...dilution won't happen. They've got gobs of cash. Cmon book more shows. Give even bigger bonuses next quarter. You deserve it!!! Good til late 2019 wasn't it!!! LMBO
Run Management Run!!! Right out the door!!!
Ok you don't have to ask. Here's the third. Care to explain how they are directly getting 100% of the funds? I won't hold my breath. Maybe Lonza will purchase the Centers running these things, and when the big Lonza deal comes any day now, it will just be like getting it all. Or Amgen could be a possibility I guess. LMBO
In September 2017, our Phase III study of PLX-PAD cells to support recovery following surgery for femoral neck fracture was awarded a Euro 7,400,000 (approximately $8,700,000) grant. The grant is part of the European Union's Horizon 2020 program. The Phase III study of PLX-PAD to support recovery following surgery for femoral neck fractures will be a collaborative project carried out by an international consortium led by Charite Universitätsmedizin Berlin, together with us, and with participation of additional third parties. The grant will cover a significant portion of the project costs. An amount of Euro 2,400,000 (approximately $2,800,000) is a direct grant allocated to us for manufacturing and other costs, and we also expect to have a direct benefit from cost savings resulting from grant amounts allocated to the other consortium members.
Most definitely are EichKing. I have invested so much time on this thing, I will go down with the ship or reap some eventual rewards. I think it's a fifty fifty gamble. And that's just to get a move above $3. New, experienced management would push it to the 80 to 90 percent chance. You've been in this longer than I, so my pessimism maybe hasn't reached your level yet. But 31 days from now, I'll be right there with you if nothing changes.
No this covers two of them sorry Allo. Free DD for you. Let me know if you want me to paste the other for ya!!! All from their lates quarterly filing. You should actually read them before you post sometimes. LMBO
In August 2016, our CLI program in the European Union was awarded a Euro 7,600,000 (approximately $9,000,000) grant. The grant is part of the European Union's Horizon 2020 program. The Phase III study of PLX-PAD in CLI will be a collaborative project carried out by an international consortium led by the Berlin-Brandenburg Center for Regenerative Therapies together with us and with participation of additional third parties. The grant will cover a significant portion of the CLI program costs. An amount of Euro 1,900,000 (approximately $2,200,000) is a direct grant allocated to us for manufacturing and other costs, and we also expect to have direct benefit from cost savings resulting from grant amounts allocated to the other consortium members. In July 2017, the consortium amended the consortium agreement, pursuant to which the original grant allocation has been amended such that we will receive an additional direct grant of Euro 1,000 (approximately $1,200). The additional direct grant was allocated to us from the total amount of the original grant.
On October 2, 2017, the nTRACK, a collaborative project carried out by an international consortium led by LEITAT a technological Institute with the mission of collaborating with companies and other entities to create economic, social and sustainable value by research and development projects and technology processes from innovation and creativity, was awarded a Euro 6,800 (approximately $8,000) non-royalty bearing grant. An amount of Euro 500 (approximately $600) is a direct grant allocated to the Company. The Company also expects to benefit from cost savings resulting from grant amounts allocated to the other consortium members. Final approval of the grant is subject to the finalization of the consortium and Horizon 2020 grant agreements.
Hey EichKing. One thing to remember. I know Filgastrim used 100% male NHP's for one of their trials, and a high percentage for their others. I seem to recall a high percentage of males for Entolomid as well. We were 100% successful treating males, as female biological differences make them more succeptible to ARS. Amd rumours of government purchase of Entolimod have been going on for a long time with nada so far.
But competition for any of our products should never be overlooked.
My post 8014 breaks it down. All was taken from their filings.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136030229
Hey Spidey. See that's where the press releases on the grants were misleading. Of the $26 million in grants, only $6.8 million comes directly to us. The rest is to the others involved. And some of that has already been accounted for. Taking $20 million out of your equations changed it quite a bit.
Thanks for the reply Spidey. I had asked that question before and never got an answer, and couldn't find one myself. Helps in knowing what's coming out of Zami's mouth.
A drug that receives Fast Track designation is eligible for some or all of the following:
More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval
More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers
Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met
Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA
Thanks for the reply Spidey. Facts are always welcomed here. I hope you are right on the ARS study. Seems reasonable to me. From the announcement of them doing the dose study to actually initiating it was 6 months, so maybe soon we will hear.
A questions for you on studies, since you seem to be involved in them somehow. Are the companies privy to ongoing results as a study progresses. Or does that information remain under wraps until the study is completed. Basically I just want to see if there's any merit to Zami saying he expects good results, could have any validation or just hope.
Hey Spidey. You are a reasonable poster, with respect from me anyways, as to your thoughtful and helpful posts. Do you really think they can get conditional approval for CLI in 2018? That would mean they would have to be half enrolled by the end of this year, since they all have to be followed for a year after. That seems extremely unlikely. I think it's highly unlikely to get half enrolled by the end of 2018!!! IC trial was painstakingly slow, and it is approximately the same number.
And then there's the question of efficacy to go along with that. In essence they are just jumping from Phase 1 to Phase 3. Historically knocks out a vast majority of candidates. But that is a concern that should get answered either way come April with IC results.
Yes the government is their most viable option for some near term approval. But the longer this pivotal trial takes to get moving, the more worrisome it becomes. Six months of crickets on that one so far. What is going on? I wish something would be mentioned on this.
Much of everyone frustration comes from management's continued inability to inform shareholders of anything. Total garbage on their part. They can say they have enough funding for these trials, but I truly don't think so. Maybe they can if they activate their cost cutting contingency plan, but at the rate they're spending cash on these useless shows, that might not even do it.
Without government money for ARS, dilution will come without a doubt and it will be painful. There's no other way except partnership, and we all know how good they are at finding one of them.
You can also accept the fact that we have inexperienced management...the whole lot of them. That will make it even more clear.
One other thing to note regarding this patent conversation. They already had to defend one of them. That's where costs can become huge. Not saying they shouldn't have patented things, just they're not worth much right now that's for sure. And they are a drain on our limited funds. Would much rather the patents than the useless shows though!!!
A patent is only worth something substantial if there is a working product behind it. Hence why millions are spent on acquisition or royalty from one. Until Pluristem gets a working product, the cost of these many patents far outweigh their value right now. If MSC's don't prove to work on any indication, the 3d bioreactor patent is worthless.
Just got in and took a look. Bush league management for such a stellar product. Just proof that someone from Pluristem reads this board. Guess that's why I never get a response from Karine.
But we got Lonza. A big behind the scene stockpile from the new bill. Liebermann asking for part of the budget to stockpile PLX. Chinese delegation coming or already gone. Huge Amgen news imminent apparently. The list goes on and on. And this is just the last week!!!
But some love em don't they. Call me whiney all you like, you don't know jack jack, if you even remotely believe what comes out of that PP's mouth. That goes for anyone!!! Jokes. LMBO.
That is a joke for sure. Lots of cheerleaderzz going all crazy with the delusional one's concocted, weekly schemes. They get a bad case of Yaki pocket syndrome when he posts. Most of them know jack Jack. Just doing a world tour on our dollar. Must be nice. End of the year is fast approaching. Some of managements most staunch supporters are showing a little chink in the armour. Let's hope for something, or a call for some expensive pink slips at least.
See cant even answer the question I asked. Just a runaround to avoid the questions. AGAIN, why the delay to get pivitol trial started. Your buddies response is nothing but a joke. What's your explanation for once.
Hey zzatt. Simple question. Why the delay of 6 months to get this pivotal trial going for a mere 50 million? Yes it's easy to comprehend the bill will decrease the red tape, I just doubt it involves Pluristem. Could in the future, but not anytime soon.
You have apparently been waiting for this "news" for approximately 624 weeks since 2005. LMBO. So I won't be holding my breath. You put the boy who cried wolf to shame to say the least.
Hey D there's been more than just FDA. Maybe should have used some. It would increase possibility, but yes, it would be the best news to date if a contract of any kind happened.
A lot of people are thinking this bill will get Pluristem a contract. I don't, at least near term. We are coming up on 6 months since dosing trial completed. Zami stated they wanted 40 to 50 million for the pivitol study. If the military wanted this so bad, they would have thrown that small amount of cash in a heartbeat. Hopefully I'm wrong and it does happen.
Also, Zami stated that other governments wouldn't be able to purchase until FDA approval. So even if it does happen it would strictly be for U.S. government. Would still be great, but a long shot IMO.
That's why I did it as well. I needed the funds though. I started late 2016 when they promised a Japanese partnership. I should have known their promises are usually a couple to many years late. You can sure buy yourself time with options though. You can probably make it to late 2019 with the same cash and same potential reward, if not better. Good luck.
Hey TC I have been doing that for a while now. Only advice I can give is don't be disappointed when they expire. I've had 2 of them expire, and boy that date comes fast. I'm hoping some open up for later next year. But will buy June when I get some funds hopefully soon. June at least covers the I/C results. Good luck.
No controller sorry. Makes zero sense any way you want to see it. Just normal market manipulation by those that do it.
We are where we are as we have phase 1 numbers period. Our biggest trial is with 20 humans. What big pharma is going to agree on a licensing agreement on Pluristem's terms without significant stats on a significant population. Sure they will throw cash as some, but not likely what the twins are asking. Just because they're phase 3, doesn't mean jack right now. They're really not a phase 3 company by normal measures. Really think about it honestly and you may see the light like I did.
Having good results from a trial with actual phase 2 enrolment numbers would change that. If I/C numbers are good, then maybe we will see a partnership with teeth. Unfortunately we have to wait until April.
I have done the same Midas. Luckily for me they didn't bite the bullet and buy until recently. If they bought many years ago when I first mentioned them would have felt worse. Hopefully one day everyone will finally get rewarded.
I'll second that with regards to IR. At least EichKing gets a response. I've only ever gotten one from Efrat, never Karine.
Hostile takeover. I'd take that in a heartbeat. Offer this company a billion and I'd never look back. I know for others, that wouldn't be nearly enough. I'd be able to retire.
No not at all. Just want others to be aware and ready to join in for the call for heads to roll with nothing significant by the year end that's fast approaching. Unlike some here, I'm not paid to be here. Just want this company to live up to expectations for once. Not asking for much really.
You are right Eichking. It is pointless. Many beliebers here like Tweens in love with their idols. Don't care what they do, eyes glossed over.
Who cares if they've promised partners for years.
Who cares they do a useless promotion and give big bonuses.
Who cares that our stock price is lower than we were 7+ years ago.
Who cares that they waste countless cash going to these useless shows
Who cares they are transparent as a brick wall
Who cares that our competition doesn't sit still
Who cares that with every passing year we keep the twins, it will cost more to can them.
Who cares that they've diluted 3 times this year, and still could be.
Who cares that a vast majority of management has zero pharma background.
Who cares that they can't get Japanese fast track started after 2 years with the go ahead.
Who cares we delayed progression of trials 2 years to focus on manufacturing side, only for it to sit mostly idle.
Who cares that nepotism ran rampant in 3 of our management team coming from Elbit.
Who cares ...endless in reality.
The list is endless when it comes to management. Throw in how we have only phase 1 data results in reality for all but ARS. Sound good three phase 3's, but the chances for them carrying over from the phase 1 results, are historically low. This thing is far from guaranteed. There is a reason that big pharma is NOT going to do a deal with Pluristem on their terms, it's because the numbers aren't there yet to support the results.
It cracks me up when someone mentions Scott Gottlieb and tries to insinuate he is talking about Pluristem. It's absurd to say the least.
ARS will hopefully be our saviour. It's out of the twins hand so there's a good shot there. I think if that fails to come to fruition in the next year, it will be lights out. I/C results if amazing, could also do the trick.
Repetitive I am yes, as long as there's beliebers around and our share price remains in the toilet, I will continue to repeat. And because your beloved one continues to pump for the sake of their employer, is also my reason. OPA!!! Oh yes, until we get real management as well!!!
But like you, I will continue to have a vested interest in this stock on the long side. Wish I spent the last 7 years on the short side that's for sure. Until they either make it or collapse, I will be there. Product has great potential, management stinks. Belieb it or not. LMBO!!!
Yes most know this site as everyone goes there often. That's where I got the CLI measures from my earlier post. Allo checks daily to see if new sites are added. He can blame ex employees or companies, when it was the decision of management who to hire. Just keep an eye on the CLI. Late 2019 is when I think we may see interim results. Hope I'm wrong but honestly, I think my date is optimistic. We will look for future presentations.
Two words...Incompetent management!!!